Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 8/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 8/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | PRF1 | P14222 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13704163 | 0.87 | QPCT (0.40) | ESR1ESR2NR1H4TYR | |
| SCHEMBL614132 | 0.83 | ESR2 (0.50) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL31270617 | 0.83 | ESR2 (0.50) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL14374103 | 0.81 | HSD17B1 (0.37) | HSD17B1HSD17B2CYP3A4CYP2C9NR1H4 | |
| SCHEMBL237510 | 0.80 | TYR (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL13704314 | 0.77 | QDPR (0.43) | NR1H4PTGS2 | |
| SCHEMBL15271030 | 0.72 | ESR1 (0.42) | CYP3A4CYP2C9ESR1ESR2NR1H4 | |
| SCHEMBL31544343 | 0.72 | ESR1 (0.42) | CYP3A4CYP2C9ESR1ESR2NR1H4 | |
| SCHEMBL616344 | 0.69 | RARA (0.46) | CYP3A4ESR1ESR2NR1H4TYR | |
| SCHEMBL677757 | 0.69 | ESR2 (0.41) | CYP3A4ESR1ESR2TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-7488494-B2 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-02-10 | — | — | US | disclosed |
| US-7488494-B2 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-02-10 | — | — | US | disclosed |
| US-7488494-B2 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-02-10 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| EP-1721903-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | Novogen Research Pty. Ltd. (AU) | 2006-11-15 | — | — | EP | disclosed |
| EP-1210341-B1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RES PTY LTD (AU) | 2006-08-02 | — | — | EP | disclosed |
| US-20060106220-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY. LTD. | 2006-05-18 | — | — | US | disclosed |
| US-20040147551-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2004-07-29 | — | — | US | disclosed |
| EP-1210341-A4 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RES PTY LTD (AU) | 2003-06-11 | — | — | EP | disclosed |
| EP-1210341-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | Novogen Research Pty. Ltd. (AU) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001017986-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106220-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, OAT, APOB | HSD17B1 246/4885HSD17B2 186/4885CYP3A4 2407/4885 |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, ESR2, GPER1 | HSD17B1 56/4885HSD17B2 44/4885CYP3A4 676/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | HSD17B1 246/4885HSD17B2 186/4885CYP3A4 2407/4885 |
| US-20040147551-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, ESR2, GPER1 | HSD17B1 60/4885HSD17B2 45/4885CYP3A4 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.